ONXX: Summary for ONYX Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 3:50am EST - Canadian Markets open in 5 hours and 40 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Onyx Pharmaceuticals Inc. (ONXX)

On Feb 9: 29.05 USD 0.00 (0.00%)

MORE ON ONXX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

ONYX Pharmaceuticals, Inc. (NasdaqNM:ONXX) Delayed quote data

Last Trade:	29.05 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	29.05
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	59.00

Day's Range:	N/A - N/A
52wk Range:	21.85 - 36.75
Volume:	0
Avg Vol (3m):	728,064
Market Cap:	1.81B
P/E (ttm):	N/A
EPS (ttm):	-0.89
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add ONXX to Portfolio

Download Data

HEADLINES

•	Coverage initiated on Onyx Pharma by Brean Murray
	Briefing.com (Wed, Feb 3)

•	Onyx Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
	PRNewswire (Tue, Feb 2)

•	Onyx and FDA agree on cancer drug study design
	AP (Tue, Feb 2)

•	UPDATE - Onyx says FDA agrees on blood cancer drug trial design
	at Reuters (Tue, Feb 2)

•	Onyx Pharmaceuticals Announces Agreement with the FDA on a Special Protocol Assessment for Planned Phase 3 Carfilzomib Combination Trial in Relapsed M
	PRNewswire (Tue, Feb 2)

•	Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development
	PRNewswire (Mon, Feb 1)

•	Wake Up! You Still Have to Pay Attention
	at Motley Fool (Fri, Jan 29)

•	5-Star Stocks Poised to Pop: Res-Care
	at Motley Fool (Fri, Jan 29)

•	67% Decline In Consumable Cost For Human Genome Sequencing Seen In 2010 By First Analysis Equity Valuation Expert
	Wall Street Transcript (Wed, Jan 27)

•	Pfizer's Great Data Won't Do Much
	at Motley Fool (Fri, Jan 22)

More Headlines for ONXX...

ANALYST

EPS Est (next year) (Dec-07) :	-0.52
EPS Est (in 2 years) (Dec-08) :	0.86
Avg Rec (current)*:	2.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that target the molecular mechanisms implicated in cancer in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•